ALEXANDER HUTTON ADVISES ON
SALE OF TRANSENDA
03/26/10
SEATTLE - Alexander Hutton is pleased to announce the sale of its client TranSenda International LLC, to BioClinica (NASD: BIOC).
TranSenda develops and markets innovative web-based, Office-Smart Clinical Trial Management Software (CTMS). Headquartered in Bellevue, Washington, TranSenda was founded in 1998. The acquisition of TranSenda was completed in March 2010.
BioClinica is a global provider of clinical trial management services. TranSenda’s acquisition will allow BioClinica to serve customers with technologies that improve efficiencies by reducing study durations and costs through integrated operational management.
“We are excited to join BioClinica as it will provide us the ability to expand our market reach and delivery to the global marketplace and fulfill the demand for our technologies,” said Robert Webber, President of TranSenda. “We expect BioClinica’s expertise, scope of quality customer relationships and their overall global presence will be catalysts to the growth of our technologies and market reach.
Mark Weinstein, CEO of BioClinica, noted, “This acquisition is an important step forward as we continue to advance our integrated eClinical solutions model and execute our strategy of bringing best-in-class technology and resources to our customers.”
TranSenda is a Microsoft Gold Certified Partner. Director of Life Sciences Industry Solutions for Microsoft, Michael Naimoli said, “Information workers in the life sciences industry are often challenged with working across many different systems throughout the clinical trial process. TranSenda has helped pharmaceutical companies address these problems, providing solutions that allow professionals to work within the familiar Microsoft Office environment.”
Commenting on the transaction John Orr, Chairman of TranSenda, said, “The process of selling a company is a complex undertaking that calls for a team of dedicated professionals. The experts at Alexander Hutton collaborated with my key staff to form one effective team. From the onset we had great chemistry. I was consistently impressed with their eagerness to help in any way at any time. Alexander Hutton not only reduced my workload, they also earned my trust and gratitude for performing a vital role.”
The transaction was led by Alexander Hutton Managing Director Scott Hardman and Senior Advisor George Futas. Commenting on the transaction, Scott Hardman said, “A major consideration for our client was the ‘fit’ with the acquirer. BioClinica is a great strategic and cultural fit for TranSenda.”
Alexander Hutton, the Seattle office of M&A International, is the most established seller of private companies in the region having completed over 180 transactions. For additional information contact Scott Hardman, a Managing Director at Alexander Hutton at 206.792.1964 or shardman@alexanderhutton.com.
Sources: Alexander Hutton, TranSenda, BioClinica.